Default header image

Investigating Carboplatin Chemotherapy As Adjuvant Treatment For Canine Splenic Hemangiosarcoma


Objective:

To gain new insights on the efficacy and utility of carboplatin in the treatment of canine hemangiosarcoma.

Background:

Carboplatin is a chemotherapeutic medication used to treat numerous cancers in human and veterinary oncology as it has a broad spectrum of clinical activity with more favourable and decreased toxicity profiles when compared to many other chemotherapies. Splenic hemangiosarcoma is an aggressive cancer in dogs with the majority of patients dying within two months after diagnosis and splenectomy if no systemic treatment is provided. Chemotherapy with doxorubicin, a potent chemotherapy medication, provides improved survival times with a median survival time of approximately 4-6 months. There is a clear need for more effective adjuvant treatment options for canine splenic hemangiosarcoma. In other forms of canine cancer, osteosarcoma as an example, efficacy is equivocal between carboplatin and doxorubicin and due to toxicity profiles, carboplatin is the recommended treatment. At the conclusion of the study we expect to gain new insights on the efficacy and utility of carboplatin in the treatment of canine hemangiosarcoma.

Incentives:

  • Carboplatin chemotherapy (4 treatments) are covered by the study

Samples required:

  • Blood sample (teaspoon) at each visit

Inclusion Criteria:

  • Confirmed diagnosis of splenic hemangiosarcoma
  • Must have already undergone splenectomy
  • No evidence of metastasis
  • No previous chemotherapy treatment

Researchers:

  • Dr. Tony Mutsaers (PI)
  • Dr Jacqueline Bowal

Contact:

Vicky Sabine (PhD), Clinical Research Coordinator, OVC
Email: ovc.clinicaltrials@uoguelph.ca; Work Cell #: 226-218-0338

Funded by OVC Pet Trust.

<Back to Current clinical trials